Tern Plc CEO Albert Sisto increases interest in company

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, announced today that on the 23rd August 2022, the Company entered into a direct subscription with Albert Sisto, Chief Executive Officer, via the Albert E Sisto Revocable Trust, for a total of 200,000 new Ordinary Shares of 0.02p pence each at an issue price of 9.9p pence per share.

The Subscription has been undertaken by the Company to allow Mr. Sisto to increase his interest in the Company, which is otherwise difficult for Mr. Sisto to do, due to his primary residency and tax status in the United States of America. The Issue Price is equal to the closing mid-market price of the Company’s Ordinary Shares on AIM on the business day prior to this announcement.

Albert Sisto’s total beneficial interest following this transaction will be 10,616,666 Ordinary Shares, representing approximately 3.01% of the voting rights in the Company’s enlarged share capital following the issue of the Subscription Shares. The FCA notification, made in accordance with the requirements of the UK Market Abuse Regulation, is appended below.

Application has been made for the 200,000 Subscription Shares to be admitted to trading on AIM, which is expected to take place on or around 30th August 2022. Once issued, the Subscription Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

Total Voting Rights

Following Admission, the Tern plc issued ordinary share capital will consist of 352,214,701 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 352,214,701. With effect from Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual...

Search